Table 2. Levels of HR, MAP and SjvO2, PjvO2 in different groups of patients at different time points.

Variables	Groups n=20	T0	T1	T2	T3
HR, frequency/min	Parecoxib	78.3±9.4	79.0±8.7	79.6±9.5	78.3±7.3
	Dexmedetomidine	77.9±8.6	78.2±6.0	81.7±8.8	78.6±7.9
	Combined	78.4±6.1	76.8±8.3	81.4±9.7	79.5±8.7
	Control	79.1±8.9	80.3±7.2	83.9±7.2	81.1±7.2
MAP, mm Hg	Parecoxib	95.3±8.2	87.2±8.5	94.5±8.1	95.7±8.3
	Dexmedetomidine	97.1±9.5	86.1±7.6	95.7±8.3	96.4±7.5
	Combined	96.4±6.7	87.5±7.8	95.6±8.1	95.8±6.9
	Control	96.8±7.4	87.3±8.3	95.3±9.0	96.5±9.3
SjvO2	Parecoxib	60.3±7.1	72.4±9.2	66.3±7.9*,#	64.3±5.6*,#
	Dexmedetomidine	61.2±8.9	73.1±7.1	66.1±5.2*,#	64.2±5.1*,#
	Combined	61.7±6.0	73.9±7.6	71.7±6.4*	68.5±5.7*
	Control	60.9±7.5	72.8±6.3	63.5±5.8	61.0±5.5
PjvO2	Parecoxib	40.7±5.0	48.9±5.4	44.7±4.5*,#	42.5±2.2*,#
	Dexmedetomidine	40.9±6.3	48.2±5.6	44.9±4.2*,#	42.2±2.0*,#
	Combined	41.3±5.8	49.5±5.7	48.3±5.1*	44.3±3.1*
	Control	41.6±5.6	49.7±6.0	41.1±4.9	41.0±1.6

HR heart rate, MAP mean arterial pressure, SjvO2 jugular venous oxygen saturation, PjvO2 jugular venous oxygen pressure.

^*P<0.05, compared with the control group;

^#P<0.05 compared with the combined group.